Animal-derived surfactants for the treatment and prevention of neonatal respiratory distress syndrome

Summary of clinical trials

J. Wells Logan, Fernando R. Moya

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Introduction: Available literature suggests that the advantage of animal-derived surfactants over fi rst-generation synthetic agents derives from the presence of surface-active proteins and their phospholipid content. Here we summarize the results of clinical trials comparing animalderived surfactant preparations with other animal-derived surfactants and with both fi rst- and second-generation synthetic surfactants. Methods: Published clinical trials of comparisons of animal-derived surfactants were summarized and compared. Comparisons emphasized differences in (1) key surfactant components attributed with effi cacy and (2) differences in published outcomes. Results: For the most important outcomes, mortality and chronic lung disease, currently available natural surfactants are essentially similar in efficacy. When examining secondary outcomes (pneumothorax, ventilator weaning, and need for supplemental oxygen), it appears that both calfactant and poractant have an advantage over beractant. The weight of the evidence, especially for study design and secondary outcomes, favors the use of calfactant. However, the superiority of poractant over beractant, when the higher initial dose of poractant is used, strengthens the case for use of poractant as well. Conclusions: Clinical trials suggest that the higher surfactant protein-B content in calfactant, and perhaps the higher phospholipid content in poractant (at higher initial dose), are the factors that most likely confer the observed advantage over other surfactant preparations.

Original languageEnglish (US)
Pages (from-to)251-260
Number of pages10
JournalTherapeutics and Clinical Risk Management
Volume5
Issue number1
StatePublished - 2009

Fingerprint

Newborn Respiratory Distress Syndrome
Surface-Active Agents
Animals
Surface active agents
animal
Clinical Trials
Therapeutics
mortality
Phospholipids
Disease
Ventilator Weaning
Proteins
evidence
Pulmonary diseases
Pneumothorax
Lung Diseases
Membrane Proteins
Chronic Disease
poractant alfa
Oxygen

Keywords

  • Bronchopulmonary dysplasia
  • Chronic lung disease
  • Phospholipids
  • Respiratory distress syndrome
  • Surfactant
  • Surfactant proteins

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Safety Research
  • Chemical Health and Safety

Cite this

Animal-derived surfactants for the treatment and prevention of neonatal respiratory distress syndrome : Summary of clinical trials. / Logan, J. Wells; Moya, Fernando R.

In: Therapeutics and Clinical Risk Management, Vol. 5, No. 1, 2009, p. 251-260.

Research output: Contribution to journalArticle

@article{0aaaacc3fab04601bfca25a760bc6650,
title = "Animal-derived surfactants for the treatment and prevention of neonatal respiratory distress syndrome: Summary of clinical trials",
abstract = "Introduction: Available literature suggests that the advantage of animal-derived surfactants over fi rst-generation synthetic agents derives from the presence of surface-active proteins and their phospholipid content. Here we summarize the results of clinical trials comparing animalderived surfactant preparations with other animal-derived surfactants and with both fi rst- and second-generation synthetic surfactants. Methods: Published clinical trials of comparisons of animal-derived surfactants were summarized and compared. Comparisons emphasized differences in (1) key surfactant components attributed with effi cacy and (2) differences in published outcomes. Results: For the most important outcomes, mortality and chronic lung disease, currently available natural surfactants are essentially similar in efficacy. When examining secondary outcomes (pneumothorax, ventilator weaning, and need for supplemental oxygen), it appears that both calfactant and poractant have an advantage over beractant. The weight of the evidence, especially for study design and secondary outcomes, favors the use of calfactant. However, the superiority of poractant over beractant, when the higher initial dose of poractant is used, strengthens the case for use of poractant as well. Conclusions: Clinical trials suggest that the higher surfactant protein-B content in calfactant, and perhaps the higher phospholipid content in poractant (at higher initial dose), are the factors that most likely confer the observed advantage over other surfactant preparations.",
keywords = "Bronchopulmonary dysplasia, Chronic lung disease, Phospholipids, Respiratory distress syndrome, Surfactant, Surfactant proteins",
author = "Logan, {J. Wells} and Moya, {Fernando R.}",
year = "2009",
language = "English (US)",
volume = "5",
pages = "251--260",
journal = "Therapeutics and Clinical Risk Management",
issn = "1176-6336",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Animal-derived surfactants for the treatment and prevention of neonatal respiratory distress syndrome

T2 - Summary of clinical trials

AU - Logan, J. Wells

AU - Moya, Fernando R.

PY - 2009

Y1 - 2009

N2 - Introduction: Available literature suggests that the advantage of animal-derived surfactants over fi rst-generation synthetic agents derives from the presence of surface-active proteins and their phospholipid content. Here we summarize the results of clinical trials comparing animalderived surfactant preparations with other animal-derived surfactants and with both fi rst- and second-generation synthetic surfactants. Methods: Published clinical trials of comparisons of animal-derived surfactants were summarized and compared. Comparisons emphasized differences in (1) key surfactant components attributed with effi cacy and (2) differences in published outcomes. Results: For the most important outcomes, mortality and chronic lung disease, currently available natural surfactants are essentially similar in efficacy. When examining secondary outcomes (pneumothorax, ventilator weaning, and need for supplemental oxygen), it appears that both calfactant and poractant have an advantage over beractant. The weight of the evidence, especially for study design and secondary outcomes, favors the use of calfactant. However, the superiority of poractant over beractant, when the higher initial dose of poractant is used, strengthens the case for use of poractant as well. Conclusions: Clinical trials suggest that the higher surfactant protein-B content in calfactant, and perhaps the higher phospholipid content in poractant (at higher initial dose), are the factors that most likely confer the observed advantage over other surfactant preparations.

AB - Introduction: Available literature suggests that the advantage of animal-derived surfactants over fi rst-generation synthetic agents derives from the presence of surface-active proteins and their phospholipid content. Here we summarize the results of clinical trials comparing animalderived surfactant preparations with other animal-derived surfactants and with both fi rst- and second-generation synthetic surfactants. Methods: Published clinical trials of comparisons of animal-derived surfactants were summarized and compared. Comparisons emphasized differences in (1) key surfactant components attributed with effi cacy and (2) differences in published outcomes. Results: For the most important outcomes, mortality and chronic lung disease, currently available natural surfactants are essentially similar in efficacy. When examining secondary outcomes (pneumothorax, ventilator weaning, and need for supplemental oxygen), it appears that both calfactant and poractant have an advantage over beractant. The weight of the evidence, especially for study design and secondary outcomes, favors the use of calfactant. However, the superiority of poractant over beractant, when the higher initial dose of poractant is used, strengthens the case for use of poractant as well. Conclusions: Clinical trials suggest that the higher surfactant protein-B content in calfactant, and perhaps the higher phospholipid content in poractant (at higher initial dose), are the factors that most likely confer the observed advantage over other surfactant preparations.

KW - Bronchopulmonary dysplasia

KW - Chronic lung disease

KW - Phospholipids

KW - Respiratory distress syndrome

KW - Surfactant

KW - Surfactant proteins

UR - http://www.scopus.com/inward/record.url?scp=75749094790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75749094790&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 251

EP - 260

JO - Therapeutics and Clinical Risk Management

JF - Therapeutics and Clinical Risk Management

SN - 1176-6336

IS - 1

ER -